Repros Gains as Androxal Meets Testosterone Study Goals

Repros Therapeutics Inc., maker of an experimental drug to restore normal testosterone levels to men with hypogonadism, gained the most in more than two years after the drug met study goals.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.